Difference between revisions of "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)-HEART & LUNGS"
(Imported from text file) |
(Imported from text file) |
||
| Line 1: | Line 1: | ||
===== [[Summary Article|'''SUMMARY''']] ===== | ===== [[Summary Article|'''SUMMARY''']] ===== | ||
1. Lung disease in lupus can manifest as pleuritic chest pain +/- effusion (most common), alveolar infiltrates, pneumonitis (with subsequent fibrosis and pulmonary arterial hypertension), and alveolar hemorrhagea | 1. Lung disease in lupus can manifest as pleuritic chest pain +/- effusion (most common), alveolar infiltrates, pneumonitis (with subsequent fibrosis and pulmonary arterial hypertension), and alveolar hemorrhagea: medical emergency. | ||
<br/> | <br/> | ||
<br/>2. The Framingham Offspring Study revealed that women ages 35-44 with SLE have a 50-fold increase in AMI. | <br/>2. The Framingham Offspring Study revealed that women ages 35-44 with SLE have a 50-fold increase in AMI. | ||
Latest revision as of 11:07, 20 March 2023
SUMMARY
1. Lung disease in lupus can manifest as pleuritic chest pain +/- effusion (most common), alveolar infiltrates, pneumonitis (with subsequent fibrosis and pulmonary arterial hypertension), and alveolar hemorrhagea: medical emergency.
2. The Framingham Offspring Study revealed that women ages 35-44 with SLE have a 50-fold increase in AMI.
3. Others: pericarditis (most common), myocarditis, & Libman-Sacks endocarditis (sterile fibrinous vegetations that can mimic IE).
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
